Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92

Blood

Volumn 102, Issue 8, 2003, Pages 2736-2740

  Harms, Dörthe O ^a   Göbel, Ulrich ^b   Spaar, Hans J ^b   Graubner, Ulrike B ^b   Jorch, Norbert ^b   Gutjahr, Peter ^b   Janka Schaub, Gritta E ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PRODRUG; TENIPOSIDE; THIOGUANINE DERIVATIVE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; FEMALE; FOLLOW UP; GERMANY; HUMAN; HUMAN CELL; INFANT; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0141923920     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2372     Document Type: Article

References (11)

1. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:359-363.
2. Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res. 1975;35:2872-2878.
3. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia [erratum appears in J Clin Oncol. 1990;8:567]. J Clin Oncol. 1989;7: 1816-1823.
4. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia [erratum appears in J Clin Oncol. 1990;8:567]. J Clin Oncol. 1989;7: 1816-1823.
5. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994;343:1188-1190.
6. Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res. 1994;18:805-810.
7. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Cox DR. Regression models and life-tables [with discussion]. J R Stat Soc B. 1972;34:187-220.
10. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14:2234-2239.
11. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42: 266-272.